Anebulo Pharmaceuticals, Inc. (ANEB)

Pharmaceutical Preparations · market cap $13M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Anebulo Pharmaceuticals (ANEB) is a micro-cap clinical-stage pharma with 2 employees and a ~$21M market cap, built around a single asset: ANEB-001, a Phase 2 candidate targeting Acute Cannabinoid Intoxication (ACI). The company carries no revenue, burns approximately $4M annually in R&D, and has disclosed no upcoming catalysts, leaving the thesis entirely dependent on eventual Phase 2 readout timing that is not currently calendared.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ANEB-001	Phase 2	Acute Cannabinoid Intoxication

Price & technical context

3-month

-8.8%

6-month

-48.4%

12-month

-86.7%

52-wk range

$0.30–$2.76

vs 50-day MA

-5.7%

vs 200-day MA

-44.0%

Realized vol

133.1%

Max drawdown

-91.0%

Daily closes through 2026-10-08. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ANEB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.